Mastering Change in Inhalation Drug Delivery

The first evidence of humans smoking Atropa Belladonna as a cough remedy can be dated back over 4,000 years. Fortunately, technology and expertise in inhalation drug delivery have improved significantly since then, offering better predictability, efficacy and safety of today’s widely used inhalation devices. The technology as we know it truly came into existence almost 60 years ago, when the pressurized metered dose inhaler (MDI) was invented. Today, these products are primarily used to treat COPD and asthma, but they are also suitable for many other therapeutic areas, including nasal drug delivery.

Spotlight

Dar Al Dawa Development & Investment Co

Dar Al Dawa is a MENA-wide leader in Pharmaceutical and consumer health products. With a history of more than 40 years. As a fully integrated Pharmaceutical company, we have a long established customer-centered approach to developing, producing, marketing and commercializing high-quality affordable medicines and wellness consumer products in emerging markets, with more than 900 people serving patients in more than 40 countries throughout Middle East, North Africa and Europe.

OTHER WHITEPAPERS
news image

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More
news image

How to optimize clinical supply chain management with Slope

whitePaper | December 15, 2022

Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More
news image

Four best practices for single-use supply chain success

whitePaper | February 16, 2023

Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More

Spotlight

Dar Al Dawa Development & Investment Co

Dar Al Dawa is a MENA-wide leader in Pharmaceutical and consumer health products. With a history of more than 40 years. As a fully integrated Pharmaceutical company, we have a long established customer-centered approach to developing, producing, marketing and commercializing high-quality affordable medicines and wellness consumer products in emerging markets, with more than 900 people serving patients in more than 40 countries throughout Middle East, North Africa and Europe.

Events